Research programme: RNA therapeutics - Keystone Nano

Drug Profile

Research programme: RNA therapeutics - Keystone Nano

Alternative Names: Anti-influenza siRNA NanoJackets; Cellular messaging influenza therapy - Keystone Nano; KN 20; miRNA-NanoJackets; mRNA-NanoJackets; NJ-siRNA; RNAi therapy - Keystone Nano; siRNA programme - Keystone Nano; siRNA-NanoJackets - Keystone Nano

Latest Information Update: 04 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Keystone Nano
  • Class Anti-infectives; Antineoplastics; RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer; Infections

Highest Development Phases

  • Research Cancer; Influenza virus infections

Most Recent Events

  • 27 Oct 2016 Research programme: RNA therapeutics - Keystone Nano is available for licensing as of 27 Oct 2016. http://www.keystonenano.com/partnering/areas_of_interest
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top